Bile Acid Retention Impairs Tumoral Antigen Presentation in MASH-HCC: Mechanisms and Implications

Study Background and Research Question

Hepatocellular carcinoma (HCC) is among the most prevalent and deadly cancers worldwide, with rising incidence of cases linked to metabolic dysfunction-associated steatohepatitis (MASH). MASH-HCC is particularly refractory to immune checkpoint blockade (ICB) therapies, posing a critical challenge for effective cancer immunotherapy. Tumor immune evasion is frequently driven by metabolic reprogramming, but the direct mechanisms connecting specific metabolic alterations to suppressed tumor immunity remain poorly elucidated. The reference study (Wei et al., Cancer Letters, 2026) investigates how bile acid retention within tumor cells may disrupt antigen presentation and intrinsic tumor suppression in MASH-HCC, and whether targeting this pathway can restore immune responsiveness.

Key Innovation from the Reference Study

This research reveals a previously unrecognized cellular axis in which bile acid accumulation, resulting from G protein-coupled receptor 120 (GPR120) activation, impairs NOD-like receptor family CARD domain containing 5 (NLRC5)-mediated major histocompatibility complex class I (MHC-I) antigen presentation. The study identifies the GPR120–bile acid–NLRC5 axis as a critical regulator of tumor antigenicity in the context of MASH-HCC. Notably, the authors demonstrate that pharmacological targeting of bile acid metabolism sensitizes tumors to anti-PD-1 immunotherapy, providing a rational basis for new combination strategies in resistant forms of liver cancer.

Methods and Experimental Design Insights

The investigators employed a combination of genetically engineered mouse models, in vitro cell culture systems, and pharmacological interventions to dissect the relationship between bile acid metabolism and immune evasion in MASH-HCC. Key methodological highlights include:

• Generation of hepatocyte-specific GPR120 knockout mice to assess the functional role of this receptor in tumor development and immune suppression.
• Use of high-fat, high-cholesterol dietary regimens to induce MASH and subsequent HCC in murine models, closely recapitulating human disease progression.
• Flow cytometry and immunohistochemistry to quantify MHC-I expression and assess antigen presentation capacity in both tumor and immune cells.
• Application of Tropifexor, a selective farnesoid X receptor (FXR) agonist, to pharmacologically reduce intracellular bile acid levels and examine the impact on antigen presentation and tumor immune response.
• Combination treatments with anti-PD-1 antibodies to evaluate synergistic effects on tumor burden and intratumoral adaptive immunity.

Protocol Parameters

• Induction of MASH-HCC: Administer high-fat, high-cholesterol diet for >12 weeks to induce steatohepatitis and HCC in mice.
• GPR120 genetic inactivation: Use hepatocyte-specific Cre-loxP system for targeted deletion.
• Antiviral cytokine assay: Apply IFN-γ stimulation at 0.5–10 ng/mL to assess downstream antigen presentation pathways in vitro.
• FXR activation: Treat with Tropifexor at 10–30 mg/kg orally, once daily, to reduce bile acid retention.
• Anti-PD-1 immunotherapy: Administer antibody (e.g., 200 μg/injection) intraperitoneally twice weekly, starting concurrently with FXR agonist.
• Assessment of MHC-I surface expression: Perform flow cytometry 48–72 hours after interventions.

Core Findings and Why They Matter

The central discovery is that GPR120 signaling, exacerbated by a lipid-rich environment, downregulates the bile acid efflux transporter ABCB11, leading to intracellular bile acid accumulation in tumor cells. This accumulation suppresses NLRC5 expression, which is essential for proper MHC-I antigen presentation. As a result, tumor cells lose their antigenicity and evade T cell-mediated immune surveillance (Wei et al., 2026). Specifically:

• Hepatocyte-specific deletion of GPR120 significantly reduced HCC incidence and improved antigen presentation in murine MASH models.
• Bile acid retention directly impaired MHC-I expression via suppression of NLRC5, a key transcriptional activator of antigen processing machinery.
• Reduction of bile acid accumulation with an FXR agonist restored MHC-I surface expression and enhanced the efficacy of anti-PD-1 therapy.
• Genetic ablation of NLRC5 abolished the immune-restorative effect of bile acid reduction, confirming NLRC5’s pivotal role in this axis.

These results establish metabolic control of antigen presentation as a driver of immune resistance in MASH-HCC, positioning bile acid metabolism as a therapeutic target to overcome ICB resistance in this challenging cancer subtype. The findings are especially relevant for researchers pursuing immunomodulatory cytokine research and macrophage activation studies, as they highlight metabolic–immune crosstalk as a modifiable factor in the tumor microenvironment.

Limitations and Transferability

While the study’s murine models and ex vivo assays provide compelling mechanistic insights, there are important limitations to consider:

• The translational applicability to human MASH-HCC remains to be validated in clinical settings, as murine metabolic and immunological responses may not fully recapitulate human disease complexity.
• Long-term effects and safety of pharmacological bile acid modulation, particularly with FXR agonists, require further investigation.
• The study focuses specifically on the NLRC5-mediated MHC-I pathway; effects on other antigen presentation or immune evasion mechanisms are less explored.

Nonetheless, the mechanistic framework offers a valuable foundation for future translational studies and therapeutic development in metabolic liver cancer.

Comparison with Existing Internal Articles

There are currently no internal articles directly addressing the GPR120–bile acid–NLRC5 axis or the intersection of metabolic reprogramming and antigen presentation in MASH-HCC. This study fills an important knowledge gap, providing a mechanistic basis for the observed resistance of MASH-HCC to immune checkpoint therapies and highlighting new research directions in tumor immunology and metabolic disease.

Research Support Resources

For researchers designing antiviral cytokine assays, macrophage activation studies, or TH1 cell differentiation assays in the context of tumor immunology, access to high-quality recombinant proteins is essential. Recombinant Mouse IFN-γ (E.coli, His & Strep, Liquid) (APExBIO P3167) offers confirmed biological activity and high purity, supporting workflows that require robust interferon gamma stimulation to dissect immune signaling and antigen presentation processes. This resource can be integrated into experimental protocols for mechanistic studies similar to those described above.